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We explored the variation in proportions of methicillin-
resistant  Staphylococcus aureus (MRSA) between and
within countries participating in the European Antimicrobial
Resistance Surveillance System and temporal trends in its
occurrence. This system collects routine antimicrobial sus-
ceptibility tests for S. aureus. We examined data collected
from January 1999 through December 2002 (50,759 iso-
lates from 495 hospitals in 26 countries). MRSAprevalence
varied almost 100-fold, from <1% in northern Europe to
>40% in southern and western Europe. MRSA proportions
significantly increased in Belgium, Germany, Ireland, the
Netherlands, and the United Kingdom, and decreased in
Slovenia. Within countries, MRSA proportions varied
between hospitals with highest variance in countries with a
prevalence of 5% to 20%. The observed trends should
stimulate initiatives to control MRSA at national, regional,
and hospital levels. The large differences between hospi-
tals indicate that efforts may be most effective at regional
and hospital levels.
S
taphylococcus aureus is an important cause of commu-
nity- and hospital-acquired infections. Infections
caused by methicillin- or oxacillin-resistant S. aureus
(MRSA) are mainly nosocomial and are increasingly
reported from many countries worldwide (1). As MRSA
strains are frequently resistant to many different classes of
antimicrobial drugs, second- and third-line antimicrobial
resistance is a growing concern (2). Surveillance of MRSA
provides relevant information on the extent of the MRSA
epidemic, identifies priorities for infection control and the
need for adjustments in antimicrobial drug policy, and
guides intervention programs (3).
In Europe, several surveillance systems collect data on
MRSA (4,5). Most collect data from specific types of hos-
pitals, for certain periods, or information related to specific
antimicrobial susceptibility patterns. The only ongoing ini-
tiative that continuously monitors antimicrobial resistance
in most European countries is the European Antimicrobial
Surveillance System (EARSS), funded by Directorate
General for Health and Consumer Protection of the
European Commission. This network connects national
surveillance systems and provides comparable and validat-
ed results of routine antimicrobial susceptibility tests (AST)
following standardized protocols from a representative set
of laboratories per country (6). Timely and detailed feed-
back is given through a freely accessible and interactive
Web site (http:\\www.earss.rivm.nl). EARSS was estab-
lished in 1998 and currently connects >600 laboratories in
28 countries, which serve >100 million people. Preliminary
EARSS results showed considerable differences in the pro-
portions of MRSA across Europe (7,8). 
We report results of antimicrobial susceptibility testing
of S. aureus blood isolates from 1999 to 2002 in Europe;
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Whale.these results show variation in the prevalence of MRSA,
including variation in its proportions at the hospital level.
To assess recent changes in the epidemiology of MRSA
within countries, we also present country-specific tempo-
ral trends in the occurrence of MRSA.
Materials and Methods
Data Collection
Data (identification number of isolate, EARSS labora-
tory code, date and type of specimen, sex and age of
patient, EARSS hospital code, hospital ward to which
patient is admitted, result of mecA gene polymerase chain
reaction [PCR], and susceptibility to several antimicrobial
drugs, including oxacillin and vancomycin) are collected
through national surveillance systems. AST results of
every first S. aureus blood isolate per patient per quarter
are submitted to the EARSS database by national data
managers. After authorization by the national representa-
tives by using standard feedback reports, national data are
included in the EARSS database and become available on
the Web site. 
Susceptibility Testing
Antimicrobial susceptibility is tested according to a
standardized protocol (5). Briefly, laboratories report
oxacillin susceptibility, preferably determined by an
oxacillin-screening plate or an oxacillin disk-diffusion test.
To confirm methicillin resistance, the minimum inhibitory
concentration (MIC) for oxacillin or the presence of mecA
gene by PCR is determined. Reporting vancomycin MIC is
recommended for MRSA isolates.
Interpretative AST results (i.e., sensitive [S], intermedi-
ate [I], and resistant [R], in accordance with defined guide-
lines) are accepted. Most (71%) of the laboratories have
adopted the guidelines of the National Committee for
Clinical Laboratory Standards (NCCLS; www.nccls.org).
Most guidelines agree that S. aureus isolates should be
considered nonsusceptible (R) to oxacillin if the MIC is ≥4
mg/L. Lower MIC breakpoints (R if MIC >2 mg/L) are
only suggested by the Deutsche Industrie-Norm (DIN)
(www.din.de) and guidelines of the Swedish Reference
Group for Antibiotics (SRGA) (www.srga.org). 
Data Analysis
We rejected observations lacking mandatory informa-
tion (i.e., laboratory code, date of specimen, either patient
identification number or month and year of birth, pathogen
code, antibiotic code, or oxacillin test result [S or R]);
duplicate records and repeat isolates from the same patient
were also rejected. Isolates with an interpretative AST
result of “R” (resistant) to oxacillin or one of its equivalents
(cloxacillin, dicloxacillin, and flucloxacillin) were defined
as MRSA. Isolates with intermediate susceptibility were
not counted as MRSA and were excluded from the analy-
ses. MRSA proportions were calculated as the number of
MRSA isolates divided by the total number of S. aureus
isolates obtained from blood cultures.
For the current analysis, data collected from January
1999 through December 2002 were used. We included
only information from hospitals with data for > 20 isolates
from countries reporting >100 isolates. To calculate time
trends for analyses of variation between hospitals, we
included only those hospitals that had participated in at
least 3 consecutive years. 
Univariate analyses were performed by using chi-square
or  t tests if appropriate. Country-specific trends in the
occurrence of MRSA over time were analyzed by using a
multivariate Poisson regression model adjusting for auto-
correlation in hospitals (e.g., attributable to possible simi-
larity in blood culturing and AST practice). We also
compared countries with respect to variation between hos-
pitals, expressed as the variance in hospital-specific MRSA
proportions. To eliminate the natural dependency between
variance and mean, the MRSA ratio was first transformed
by power (Box-Cox) transformation according to the fol-
lowing formula: T(k/n) = (k/n)λ, where T is the transformed
MRSA ratio, k/n is the resistance rate (i.e., the number of
resistant isolates divided by the total number of isolates),
and λ was chosen in such a way that variance was inde-
pendent of the mean, i.e., λ = 0.397. The variance was fur-
ther adjusted by size (in terms of number of isolates
reported) of individual hospitals. Country-specific vari-
ances were then graphically displayed and compared. 
Results
From January 1999 through December 2002, EARSS
received AST results of 53,264 S. aureus blood isolates
from 27 countries (Norway does not report S. aureus
data), including 628 laboratories serving 896 hospitals.
Twenty-six countries reported AST results of >100 iso-
lates. The current study included 50,759 isolates from 428
laboratories serving approximately 500 hospitals. Overall,
20% of these isolates were reported as methicillin resist-
ant. Atotal of 295 hospitals (35,921 isolates, 19 countries)
provided data for at least 3 consecutive years and were
included in the time trend analyses. Table 1 describes the
main characteristics of the data and the proportion of
MRSA by country. 
MRSA was more frequently isolated from men (21%)
than from women (18%, p < 0.001). Patients with a blood
culture positive for MRSA were older than patients with
methicillin-susceptible S. aureus (MSSA) (mean age, 65.3
[SD 18.7] versus 58.6 [23.4], p < 0.001). The proportion of
MRSA was highest among patients admitted to intensive
care units (35%). 
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RESEARCHGeographic variation is displayed in Figure 1, which
shows a north-south gradient, with the lowest MRSA
prevalence in northern Europe and highest prevalence in
southern Europe, Israel, the United Kingdom, and Ireland.
MRSAproportions varied almost 100-fold, with the lowest
proportion in Iceland (0.5%) and the highest proportion in
Greece (44%, Table 1).
Statistical analyses of country-specific time trends by
Poisson regression (Table 2) showed that increases in
MRSAproportions were significant in Belgium (from 22%
in 1999 to 27% in 2002), Ireland (39%–45%), Germany
(9%–19%), the Netherlands (0.4%–1%) and the United
Kingdom (31%–45%). The proportion of MRSAdecreased
significantly in Slovenia only, from 22% in 2000 to 15% in
2002. The model had difficulties in estimating changes in
MRSA proportion in countries with low counts of MRSA
isolates, which is reflected in the very wide confidence
intervals for Iceland and Bulgaria (Table 2). Relatively
large year-to-year fluctuations occurred in some countries
(Bulgaria, Greece, Luxembourg, Malta, and Portugal);
some of these countries (Bulgaria, Luxembourg, and Malta)
had low isolate counts (Table 1). Figure 2 presents signifi-
cant time trends by showing MRSA proportions per coun-
try per year for 1999 through 2002.
Figure 3A shows regional variation in MRSA propor-
tions within countries. Particularly high variation was
identified among hospitals in Belgium, the Czech
Republic, Spain, Greece, Italy, Portugal, and the United
Kingdom. After applying the power transformation, the
remaining variation was highest in Germany (Figure 3B),
with a variance after transform of 17%. Other countries
with relatively high variation in MRSA proportions (vari-
ance after transform >15%) between hospitals were
Poland, the Czech Republic, and Slovakia. The highest rel-
ative variation was found in countries with MRSApropor-
tions from 5% to 20%, with the exception of Hungary and
Slovenia. Arelatively high variation between hospitals was
also found in countries with MRSA proportions >25%.
The lowest variation between hospitals was observed for
Slovenia (variance after transform, 3%), and variation was
also low in France (variance after transform, 5%). 
Vancomycin resistance did not occur. Intermediate sus-
ceptibility of S. aureus (VISA) was only reported for five
isolates from France in 2001.
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Table 1. Characteristics of EARSS database by countries
a,b
Country (EARSS country code)  No. of hospitals
c
Total no. of 
isolates  No. of MRSA isolates (%)  Period of participation 
Austria (AT)  11  656  58  (8.8)  Jan 2000–Dec 2002 
Belgium (BE)  36  2,953  696 (23.6)  Jul 1999–Dec 2002 
Bulgaria (BG)  4  183  62 (33.9)  Jan 2000–Dec 2002 
Croatia (HR)  6  341  125 (36.7)  Jul 2001–Dec 2002 
Czech Republic (CZ)  35  2,426  142 (5.9)  Apr 2000–Dec 2002 
Denmark (DK)  22  2,406  14 (0.6)  Jan 1999–Sept 2002 
Estonia (EE)  3  112  1 (0.9)  Jan 2001–Dec 2002 
Finland (FI)  17  1,990  19 (1.0)  Jan 1999–Dec 2002 
France (FR)  24  3,376  1,117 (33.1)  Jan 2001–Dec 2002 
Germany (DE)  25  3,757  600 (13.8)  Jan 1999–Dec 2002 
Greece (GR)  19  1,126  500 (44.4)  Jan 1999–Dec 2001;  
Jul 2002–Dec 2002 
Hungary (HU)  12  435  31 (7.1)  Jan 2001–Dec 2002 
Iceland (IS)  1  184  1 (0.5)  Jan 1999–Dec 2002 
Ireland (IE)  19  2,897  1,192 (41.2)  Jan 1999–Dec 2002 
Israel (IL)  5  849  326 (38.4)  Jan 2001–Dec 2002 
Italy (IT)  57  3,593  1,470 (40.9)  Jan 1999–Jun 2000;  
Apr 2001–Dec 2002 
Luxemburg (LU)  4  214  41 (19.2)  Jan 1999–Dec 2002 
Malta (MT)  1  240  105 (43.8)  Jan 2000–Dec 2002 
Netherlands (NL)  45  5,359  30 (0.6)  Jan 1999–Dec 2002 
Poland (PL)  8  238  42 (17.7)  Jan 2001–Dec 2002 
Portugal (PT)  15  1,540  535 (34.7)  Jan 1999–Dec 2002 
Slovakia (SK)  7  228  24 (10.5)  Jul 2001–Dec 2002 
Slovenia (SI)  8  657  121 (18.4)  Jul 2000–Dec 2002 
Spain (ES)  35  2,985  739 (24.8)  Jan 2000–Dec 2002 
Sweden (SE)  54  6,071  48 (0.8)  Jan 1999–Dec 2002 
United Kingdom (UK)  27  5,343  2,217 (41.5)  Jan 1999–Sept 2002 
Total 500  50,759  10,256  (20.2)   
aEARSS, European Antibiotic Resistance Surveillance System; MRSA, methicillin-resistant Staphylococcus aureus. 
bOnly hospitals providing data of !20 isolates are included. 
cAccording to EARSS hospital codes provided by the countries. Discussion
This is the first EARSS report on the prevalence of
MRSA among blood isolates in 27 countries in the
European region. We found that proportions of MRSA
vary largely across Europe, with the highest proportions in
southern and parts of western Europe and lowest propor-
tions in northern Europe. MRSA proportions seem to be
increasing in many countries. Significant increases were
found for Belgium, Germany, the Netherlands, Ireland, and
the United Kingdom, whereas the proportion of MRSA
decreased in Slovenia. In all countries, variation between
hospitals was observed. The variation between hospitals
was highest in Germany and in most other countries with
an MRSA prevalence of 5% to 20%. The lowest variation
between hospitals was found in Slovenia.
Our results show the European situation with respect to
the occurrence of MRSA in blood isolates and confirm
other observations (9–11) on invasive isolates; they are
also in accordance with findings of other studies with
respect to demographic variables, such as sex, age, and
patient ward (9,12). Although blood isolates represent the
minority of clinically relevant samples, they are indicative
of infection. Studies that report MRSA proportions from
all sources usually include screening samples that are sub-
ject to bias because of differential screening practices.
Considering hospital-acquired MRSA only seems to pro-
vide insight into the European MRSA epidemic, as the
prevalence of community-acquired MRSA in Europe
remains very low (0.03%–1.5%), even in countries with a
high MRSA prevalence in hospitals (13–17). EARSS pro-
vides comparable data, annually validated through external
quality assurance exercises, which have repeatedly con-
firmed a good-to-excellent concordance for identifying
MRSA (18).
EARSS accepts susceptibility data according to clinical
breakpoints (S, I, R) in agreement with international guide-
lines. Methicillin resistance is usually defined as having an
MIC of >4 mg/L. Because of lower breakpoints (MIC >2
mg/L) defined by SRGA and DIN, this definition may
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Figure 1. Geographic variation in proportions of methicillin-resist-
ant Staphylococcus aureus (MRSA) (1999–2002).
Table 2. Relative change in MRSA proportion per country per year and 95% confidence intervals as calculated from Poisson 
regression models 
a,b,c 
Country 
Reported % 
MRSA at start 
Reported % 
MRSA in 2002 
Relative change per 
year, ratio  95% CI of estimated change 
 
p value 
Austria 7.0
d  7.6  0.80  0.48  – 1.34  0.39 
Belgium  22.1  27.2  1.25  1.12 – 1.41  0.01 
Bulgaria 35.1
d  37.7  1.11  0.59 – 2.09  0.76 
Czech Republic  4.5
d  6.2  1.15  0.89 – 1.50  0.29 
Denmark  0.3  1.0  1.64  0.97 – 2.75  0.06 
Finland  1.5  0.8  0.69  0.43 – 1.11  0.13 
Germany  9.4  19.2  1.72  1.54 – 1.93   0.01 
Greece  37.0  48.6  1.23  0.89 – 1.71  0.21 
Iceland  0.0  0.0  0.52  0.07 – 3.67  0.51 
Ireland  39.4  45.0  1.36  1.17 – 1.58  0.01 
Italy  35.2  40.0  1.11  0.94 – 1.30  0.23 
Luxembourg  15.0  18.3  1.09  0.71 – 1.67  0.70 
Malta 34.7
d  42.5  1.58  0.92 – 2.74  0.10 
Netherlands  0.4  1.0  1.62  1.01 – 2.58  0.04 
Portugal  39.7  38.9  0.91  0.75 – 1.09  0.32 
Slovenia 22.3
d  14.7  0.69  0.51 – 0.93  0.02 
Spain 28.4
d  23.5  1.03  0.87 – 1.21  0.74 
Sweden  1.1  0.7  0.95  0.73 – 1.23  0.68 
United Kingdom  30.5  44.5  1.48  1.31 – 1.66  0.01 
aCI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus. 
bAdjusted for autocorrelation within hospitals and for variation in the number of isolates per quarter, including only the hospitals participating for at least 3 
consecutive years and reporting data of > 20 isolates. 
cThe change estimated by the model does not necessarily correspond to the overall change that can be calculated from the second and third column, this 
is because some trends first show an increase, followed by a decrease, or vice versa. 
dData from year 2000 onwards. have caused partial overestimation of MRSA proportions
reported from Sweden (where SRGA is used in 100% of
laboratories), and from Germany (where DIN is used in
59% of the participating laboratories) in comparison to
other countries (19). However, most MRSA strains show
high-level resistance to oxacillin, although low-level
resistant strains are emerging (20). Moreover, such mis-
classification is unlikely to bias the country-specific tem-
poral trends reported here. In all other countries, all
laboratories agree on a single breakpoint (>4 mg/L). 
We used Poisson regression modeling adjusting for
autocorrelation within hospitals to test for possible time
trends in MRSA proportions. This model assumes that the
epidemic runs according to an S-curve (21). The results of
this analysis need to be interpreted with caution, as confi-
dence intervals are wide, especially for countries with a
low number of isolates. Year-to-year fluctuations found for
some countries were probably not due to changes in the
case-mix, as analyses were performed on data from a con-
stant set of hospitals in each country, but were possibly
caused by random variation of low numbers of isolates
(Bulgaria, Luxembourg, Malta). Since the model estimates
time trends over the 4-year observation period, it did not
account for such fluctuations, which should be possible by
autoregressive moving average (ARIMA) modeling (22).
However, ARIMA modeling requires at least 60 data
points, which cannot be provided at this stage.
The temporal increase we found for Germany is sup-
ported by a national surveillance study carried out at regu-
lar intervals, which reported an increase of MRSA from
2% in 1992 to 21% in 2001 (23,24). Our results for the
United Kingdom show that the increase in MRSA propor-
tions, reported from 1992 through 1998 (25,26), continued
until 2001, and now appears to have leveled off. This
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Figure 2. Statistically significant trends (p < 0.05) in methicillin-
resistant Staphylococcus aureus (MRSA) proportions per year by
country, 1999–2002, including hospitals participating for at least 3
consecutive years and reporting data of >20 isolates only.
Figure 3. A) Variation in methicillin-resistant Staphylococcus
aureus (MRSA) proportions between hospitals with AST results of
>20 blood isolates, displayed by ranking of MRSAproportion (from
lowest to highest). Only countries with more than one hospital are
displayed. Hospital-specific proportions (open diamonds) are
grouped per country. The solid vertical bars represent the mean
MRSA proportion per country. B) Local variation, showing the
power-transformed variance being independent of the mean
MRSA proportion per country, displayed by ranking of MRSA pro-
portion (from lowest to highest). Only hospitals reporting >20 iso-
lates are included. Countries with less than five reporting hospitals
are not shown (Iceland and Malta [1], Estonia [3], Bulgaria and
Luxembourg [4]).
B
Adevelopment in the MRSA epidemic reflects the curve of
the number of hospitals affected by MRSAoutbreaks over
time, as predicted by Austin and Anderson (21). The same
epidemic curve might apply to Ireland, although the stabi-
lizing MRSA prevalence may also be the result of a
nationwide infection control campaign (27). This Strategy
for the Control of Antimicrobial Resistance in Ireland
(SARI) follows a multidisciplinary approach, focusing on
surveillance of antimicrobial resistance and use as well as
infection control and stewardship of antibiotic use in the
community and in hospitals. National MRSA guidelines
are being updated, and the deficit in hospital staffing (lab-
oratory surveillance scientists, infection control nurses,
clinical microbiologists, and clinical pharmacists) is cur-
rently being addressed (28). In England, several recent
initiatives have the goals of increasing awareness and
encouraging efforts to control MRSAby individual hospi-
tals. First, a mandatory surveillance program for MRSA
bacteremia was launched, which included publication of
MRSA diagnoses by named health trust (29,30). Second,
a strategy was published to reduce healthcare-associated
infection in England (31), which included guidelines for
good hospital practice. The rise in MRSA prevalence in
the Netherlands might be the result of the increase in het-
erogeneously resistant clones with low MICs for oxacillin
(4–24 mg/L) (32). The effects of national infection control
campaigns launched in Slovenia (J. Kolman, pers. comm.)
may have had an impact. With the continuation of
EARSS, we will be able to monitor any effect of such
campaigns.
Variations in MRSA proportions between hospitals
within the same country have been reported (9,33–35), but
to our knowledge, this is the first attempt to quantify vari-
ation between hospitals at the national level in a European
study. We showed that considerable variation in MRSA
proportions exists not only between countries but also
between hospitals within a country. Regional variation
might be explained by different phenomena. The emer-
gence of MRSA is largely due to dissemination of clonal
strains, and temporary hospital outbreaks are typically due
to clonal expansion (36). If stringent control measures are
taken to prevent further MRSA transmission, MRSA
prevalence might subsequently be reduced to sporadic lev-
els (12). However, the effectiveness of MRSA control
depends on several factors, such as the existence and cor-
rect application of hygiene protocols to prevent transmis-
sion (hand hygiene, isolation practices, cohorting), level of
care needed by patients (indicating host susceptibility),
and antimicrobial drug prescription policies (which would
influence selective pressure), which might differ between
hospitals in a country (37). As Kotilainen and colleagues
showed, quick and adequate measures at the hospital level,
as well as at the regional level, may be successful in con-
taining the MRSA epidemic (38). Regional variation may
also be explained by differences in diagnostic practice and
culturing activity and random errors, which may artificial-
ly increase variation (39). Also, a differential case-mix
attributable to differences in the level of care provided per
hospital and differential referral practice may confound
our estimates (9,35,40). However, unusually high variation
in MRSA proportions between hospitals seems to occur
most often in countries experiencing a current surge of
MRSA. In support of this hypothesis, in general, MRSA
proportions varied most in countries with increasing and
intermediate (5%–20%) MRSA prevalence. These coun-
tries might have changed from equilibrium with adequate
control and elimination of sporadic MRSA and might be
on the verge of becoming MRSA-endemic. This stage may
be characterized by abandoning strict search-and-control
strategies and adopting more flexible approaches, as hap-
pened in England when MRSA prevalence was increasing
in the 1990s (41,42). However, MRSA proportions were
not increasing in all these countries, and variation in preva-
lence between hospitals was also high in countries with a
high overall MRSAprevalence (>25%) (37). In contrast, in
Slovenia, where MRSA proportions have decreased
recently, variation between hospitals was low. Thus, the
national campaign on infection control might have
decreased not only MRSA prevalence but also the varia-
tion in MRSA proportions between hospitals. 
Our database did not show vancomycin resistance; a few
VISAisolates were reported from France only. This finding
might be explained by the fact that EARSS collects routine
data, whereas VISAwill only be detected in specialized lab-
oratories. Moreover, the clinical and epidemiologic impor-
tance of (heterogeneous) VISA remains to be clarified.
EARSS results show that MRSA proportions increased
in several countries. Variation in MRSA proportions exists
at international and at national levels, and regional variation
seems to be highest in countries with intermediate MRSA
proportions (5%–20%). Although the reasons for this phe-
nomenon are unknown, high variation may occur in coun-
tries where the epidemiology of MRSA is in a transition
period (e.g., Germany). Also in countries with a high
MRSAproportion, between-hospital variation remains con-
siderable. The large differences between hospitals indicate
that initiatives may be most effective when undertaken at
the local or regional level (38). To combat the MRSA epi-
demic, public health researchers and all health profession-
als must understand the role of hospital hygiene protocols
and of antimicrobial drug policies, as well as mechanisms
of regional spread of MRSA throughout hospitals. Studies
that link information on MRSA guidelines, antimicrobial
policies, and prescriptions with resistance rates at the level
of the hospital, region, or both, may increase our under-
standing of the nature of the MRSA epidemic (43). 
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